CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

Is Cardiac Diastolic Dysfunction a Part of Post-Menopausal Syndrome? Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction Nocturnal thoracic volume overload and post-discharge outcomes in patients hospitalized for acute heart failure Percutaneous Atriotomy for Levoatrial–to–Coronary Sinus Shunting in Symptomatic Heart Failure: First-in-Human Experience Heart Failure With Improved Ejection Fraction-Is it Possible to Escape One’s Past? A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF) Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors

Clinical TrialFebruary 6, 2018, Volume 137, Issue 6

JOURNAL:Circulation Article Link

Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study

M .Kosiborod, CVD-REAL Investigators and Study Group. Keywords: SGLT2 inhibitor; death; diabetes mellitus; heart failure; observational studies

FULL TEXT PDF